Democritus University of Thrace (DUTH)
Η συστηματική θεραπευτική αντιμετώπιση του μη εγχειρήσιμου καρκίνου του παγκρέατος
Abstract
dc:descriptionAim: To evaluate the efficacy, the toxicity and the clinical benefit of gemcitabine combined with docetaxel, irinotecan or capecitabine in patients with inoperable or metastatic pancreatic cancer. We also assessed the effect of age, sex, primary location of the tumor, presence of liver metastases, stage and the response to therapy, on survival and/or treatment choice. Material and methods: 167 patients with advanced pancreatic cancer (st.II, III, IV) were enrolled. 54 pts received the combination of gemcitabine and docetaxel, 60 pts the combination of gemcitabine and irinotecan and 53 pts the combination of gemcitabine and capecitabine. Gemcitabine was given on days 1 and 8 at dose of 1000mg/m2, docetaxel at a dose 100mg/m2 on day 8, Irinotecan at 300mg/m2 on day 8 and capecitabine at dose 1300mg/m2/d p.os divided into two equal doses on days 1-14. Treatment was repeated every 3 weeks. We evaluated the compliance to treatment, response to treatment, survival and toxicity of the regimens. Parameters such as age, sex, primary location, liver metastases, stage and response to therapy effecting on median survival were also investigated using univariate and multivariate analysis models. Results: 1) Gemcitabine plus Docetaxel: A total of 218 cycles were administered. The median duration of response was 5.6 months, the median time to tumor progression (TTP) was 7.4 months and the median survival 6.5 months. Partial response was documented in 13% of the pts and stable disease in 33%. Pain improvement as a result of treatment was observed in 60% of the pts, weight gain in 33% and improvement in P.S in 33%. 2) Gemcitabine plus Irinotecan: A total of 329 cycles were administered. The median duration of response was 5 months, the TTP was 7 months and the median survival was 7 months. There was 1 complete response (1.7%), partial response in 23.3% and stable disease in 36.7% of the pts documented. Pain improvement was observed in 45% of the pts, weight gain in 19.5% and P.S improvement in 48.9%. 3) Gemcitabine plus Capecitabine: A total of 304 cycles were administered. The median duration of response was 5 months, the TTP was 7 months and the median survival was 7 months. Partial response was documented in 18.9% of the pts and stable disease in 41.5%. Pain improvement was observed in 81% of the pts, weight gain in 36% and P.S improvement in 3%. Conclusions: The results reported hereby are among the best in the literature. The statistical analysis showed that patients with partial response to treatment or disease stabilization have a significantly better survival as compared with non-responders. The presence of liver metastases is a parameter with a strong effect on survival. In summary, the present study demonstrated that gemcitabine-based combination chemotherapy is active and well tolerated. In a patient population with poor prognostic features such as patients with advanced pancreatic cancer they should be encouraged to participate in trials with novel cytotoxic agents, in order to establish new standards in the treatment of this disease.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2005
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Amarantidis, Kyriakos
- Αμαραντίδης, Κυριάκος
Subjects
dc:subject × 18- Καρκίνος παγκρέατος
- Ανεγχείρητη νόσος
- Χημειοθεραπεία
- Κλινικό όφελος
- Γεμσιταβίνη - δοσεταξέλη
- Γεμσιταβίνη - ιρινοτεκάνη
- Γεμσιταβίνη - καπεσιταβίνη
- Pancreatic cancer
- Inoperable disease
- Chemotherapy
- Clinical benefit response
- Gemcitabine - docetaxel
- Gemcitabine - irinotecan
- Gemcitabine - capecitabine
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17587